Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Edward D. Hall

Edward D. Hall

Professor
University of Kentucky Chandler Medical Center
Lexington

Biography

After completing his Ph.D. in neuropharmacology from the Cornell University Graduate School of Medical Sciences and a post-doctoral fellowship at Cornell University Medical College, he joined the Northeastern Ohio Universities College of Medicine where he rose to the rank of Associate Professor of Pharmacology with tenure. Having developed a strong interest in drug discovery and development, he moved to the The Upjohn Company where he initiated and led an effort over many years to discover agents for the treatment of traumatic brain and spinal cord injury and stroke. He played a leading role in the discovery and development of high dose methylprednisolone therapy for acute spinal cord injury. In addition, Dr. Hall was co-discoverer of the 21-aminosteroids (“lazaroids”) including tirilazad mesylate which was the subject of phase III clinical trials and was approved for the treatment of aneurysmal subarachnoid hemorrhage in several European and Australasian countries. For this work, he received the Fred Kagan Lead-Finding Award for Outstanding Achievement in Discovery Research, the Upjohn Achievement in Science and Medicine Award and was elected to the National Spinal Cord Injury Association SCI Hall of Fame. After 15 years, Dr. Hall left Upjohn and joined Parke-Davis Pharmaceutical Research which is now part of Pfizer Global Research and Development (PGRD). In 2001, he was appointed Senior Director, CNS Pharmacology at PGRD-Ann Arbor. In July, 2002, he returned to academia at the University of Kentucky Medical Center where he was Director of the Spinal Cord and Brain Injury Research Center (SCoBIRC) for the next 10 years. Dr. Hall is an authority on the pathophysiology of acute neurological injury, particularly the role of reactive oxygen mechanisms, and the design and development of antioxidant neuroprotective drugs. His ongoing NIH-funded research is directed at the discovery of novel neuroprotective pharmacological strategies for acute neurotrauma.

Research Interest

Anatomy & Neurobiology, Neurology, Neurosurgery and Physical Medicine & Rehabilitation